Journal of cannabis research最新文献

{"title":"The potential of hemp roots, microgreens and leaves for human nutrition.","authors":"Harpal Singh, Tobias Kretzschmar, Ashley Dowell, Nadia Toppler, Andrew Kavasilas, Jos Mieog","doi":"10.1186/s42238-025-00319-2","DOIUrl":"10.1186/s42238-025-00319-2","url":null,"abstract":"<p><p>Cannabis sativa L. has been utilised for food, fibre and medicine for millennia. However, historical legal constraints due to the presence of psychoactive cannabinoids have limited the use of the plant for human nutrition. For instance, in Australia, only dehulled hemp seeds and their derivatives have been available for human consumption since 2017, while the nutritional potential of other tissues remains overlooked. In this study, hemp leaves, roots and microgreens from cultivar HAN NE were analysed to determine their nutritional properties, including minerals, vitamins, terpenes, amino acids, and proximate data. Furthermore, cannabinoid contents were determined in target tissues, together with the expression of key genes involved in cannabinoid biosynthesis. Results highlighted the potential role of hemp leaves and microgreens in human nutrition, being able to provide a good source of protein, vitamin E, and various other essential micronutrients and minerals. The cannabinoid pathway was found to be active in microgreens and young leaves but not in roots, reflected by the measured cannabinoid concentrations in these tissues, which emphasised the importance of picking suitable cultivars for leaf and microgreens. Additionally, arsenic accumulation was observed in the roots, highlighting an important aspect of using roots for human nutrition.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"75"},"PeriodicalIF":4.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12502590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What proportion of people who use cannabis in Germany have spoken with their general practitioner about their consumption? A repeated cross-sectional representative population survey.","authors":"Benjamin Borchardt, Stephanie Klosterhalfen, Daniel Kotz","doi":"10.1186/s42238-025-00329-0","DOIUrl":"10.1186/s42238-025-00329-0","url":null,"abstract":"<p><strong>Introduction: </strong>On April 1st, 2024, Germany's cannabis legalisation bill entered into force. It is unknown what effect the legal changes could have, if any, on the prevalence of cannabis use. Preventive measures of cannabis-related health impacts are best possible if harmful use is recognised and addressed at an early stage. Our aim was to estimate the proportion of people who used cannabis in Germany that discussed their cannabis consumption with their general practitioner (GP), on the initiative of either the GP or the patient, and how these varied according to person characteristics.</p><p><strong>Methods: </strong>We used data from the German Study on Tobacco Use (DEBRA). This is a repeated ongoing representative cross-sectional household survey on the use of tobacco and alternative nicotine delivery systems in Germany in people aged 14 years and older. In bi-monthly study waves we asked all respondents who stated that they had consumed cannabis before whether they had ever spoken with their GP about their cannabis use or received advice about it. We estimated the proportion including 95% confidence intervals and assessed possible associations with person characteristics using univariate logistic regression models.</p><p><strong>Results: </strong>Of 2,057 people who have ever used cannabis, 7.0% [95%CI = 5.9; 8.2%] (n = 139) reported having spoken to their general practitioner about their cannabis use or having sought advice in this regard. This response was associated with older age (65 +), low educational attainment, low income and frequent cannabis use. Conversation with a GP was also more common among people who had used cannabis in the past year (16.2%; 95%CI = 13.5; 19.6%).</p><p><strong>Conclusions: </strong>Around one in fifteen people who have used cannabis before has ever spoken with his or her GP, or received advice, about his or her cannabis consumption. In people with past-year and especially frequent use, the proportions are highest, ranging between 16 to 26%. The awareness of this topic among GPs needs to be increased. Furthermore, a future re-evaluation of what impact cannabis legalisation will have on the frequency of consultation about cannabis consumption in primary care is necessary.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"76"},"PeriodicalIF":4.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of non-psychotropic Cannabis sativa L. standardized extracts in a model of intestinal inflammation.","authors":"Nicole Maranta, Giulia Martinelli, Marco Fumagalli, Carola Pozzoli, Elisa Sonzogni, Nora Rossini, Umberto Ciriello, Giuseppe Paladino, Mario Dell'Agli, Stefano Piazza, Enrico Sangiovanni","doi":"10.1186/s42238-025-00335-2","DOIUrl":"10.1186/s42238-025-00335-2","url":null,"abstract":"<p><strong>Background: </strong>The use of Cannabis sativa L. (Cannabis) was reported by observational studies on inflammatory bowel diseases (IBD) patients. However, this indication is poorly supported by clinical trials. Several pre-clinical studies demonstrated the anti-inflammatory activity of Δ⁹-tetrahydrocannabinol (Δ⁹-THC) and cannabidiol (CBD) at intestinal level. On the contrary, minor cannabinoids, such as cannabigerol (CBG), were less investigated. Moreover, several authors suggested that complex Cannabis extracts might display a higher efficacy in respect to pure cannabinoids against inflammatory disorders.</p><p><strong>Methods: </strong>This study was aimed at investigating the role of Cannabis extracts, standardized in CBD and CBG content, in a model of in vitro-induced intestinal inflammation using CaCo-2 cells. Inflammatory mediators at transcriptional (PCR arrays) and protein level (ELISA assays) were investigated and correlated with enterocyte layer permeability. The two evaluated extracts, A and B, come from the mix of the same Cannabis varieties (Cannabis sativa L. Chemotype III and Chemotype IV), and are standardized in CBD and CBG at the same level, by changing the polarity of the primary extraction solvents.</p><p><strong>Results: </strong>Pro-inflammatory cytokines involved in IBD, such as IL-1β and IFN-γ, induced the expression and the release of chemokines for lymphocytes (CXCL-9, CXCL-10, CCL20) in CaCo-2, while Cannabis extracts (100 µg/mL) or individual compounds (8 µM) showed inhibitory activity. After simulated digestion, extract A abrogated the release of CCL-20, while extract B abrogated the release of CXCL-9 and CXCL-10. The inhibition of CXCL-9 was demonstrated at transcriptional level also. The inhibitory activity paralleled with the content of CBD or CBG, acting at least in part through NF-κB impairment (-42% and - 66%, respectively). However, Cannabis extracts showed greater effect in the CaCo-2-THP-1 co-culture inflammation model compared to individual cannabinoids, thus partially recovering the epithelial barrier measured by transepithelial electrical resistance (TEER), and zonula occludens (ZO-1) expression.</p><p><strong>Conclusions: </strong>Data collected within this study showed the importance of standardization and extraction method reproducibility through manufacturing and process control, besides demanding future investigations focusing on the effect of Cannabis extracts against intestinal inflammation, which show in this context effects higher than individual cannabinoids.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"74"},"PeriodicalIF":4.3,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12502145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical assessment of pharmacokinetics and anticonvulsant activity of CBDTech, a novel orally administered cannabidiol (CBD) formulation for seizure and epilepsy.","authors":"Jacob D McDonald, Feng Zhou, Justyna Kulpa, Philip J Kuehl","doi":"10.1186/s42238-025-00322-7","DOIUrl":"10.1186/s42238-025-00322-7","url":null,"abstract":"<p><p>Oral cannabidiol (CBD) product use is increasing despite suboptimal pharmacokinetics (PK) of currently available formulations. This study aimed to investigate the PK of CBD formulated using the drug delivery technology DehydraTECH™, which is hypothesized to increase absorption by bypassing first-pass liver metabolism due to enhanced lipophilic composition. Anticonvulsant activity of the leading formulation was investigated in the maximal electroshock seizure (MES) model. For the PK studies, Sprague Dawley rats were orally administered 25 mg/kg CBD in MCT oil or test formulations incorporating DehydraTECH™ (n = 10 per group). Plasma, brain tissue and urine and feces samples were collected to determine comparative absorption, distribution, and excretion by liquid chromatography with tandem mass spectrometry (LC-MS/MS). For the efficacy studies, a series of experiments was conducted using the lead formulation (CBDtech) from the PK trial. Effective dose (ED) of CBDtech in comparison to Epidiolex® (50-100 mg/kg), time of peak efficacy (TPE), and median ED (ED50) were assessed in the acute MES model. Clinical observations, presence/absence of hind limb extension (HLE), and maximum seizure severity (MSS) were recorded. No abnormal clinical signs were observed following dosing in any study. Area under the curve from dosing to the last measurable concentration (AUC_last) was 391 to 2708% improved following treatment with DehydraTECH™ formulations as compared with the MCT control (all p < 0.01). CBD was detected in brain, urine, and feces samples following all DehydraTECH™ treatments. Treatment with the ED of CBDtech (75 mg/kg) resulted in full protection (absence of HLE) in 66.6% of test subjects following MES test compared to 50% in the Epidiolex® group. The one-hour timepoint was determined to be the TPE for CBDtech; HLE was absent in 75% of animals and partial in 12.5% of animals. In comparison, in the Epidiolex® group HLE was absent in 50% of animals and partial in 12.5% of animals. The calculated ED50 was 75 mg/kg. Formulation of CBD with DehydraTECH™ resulted in improved bioavailability and efficacy in an acute seizure model. These findings contribute to a deeper understanding of CBD PK and will aid in the design of more effective CBD-based therapeutic interventions.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"73"},"PeriodicalIF":4.3,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of cannabidiol on nitric oxide synthases: a narrative review on therapeutic implications for inflammation and oxidative stress in health and disease.","authors":"Seyed Amin Alavi Hooshmand, Maryam Rameshrad, Amirhossein Sahebkar, Mehrdad Iranshahi","doi":"10.1186/s42238-025-00332-5","DOIUrl":"10.1186/s42238-025-00332-5","url":null,"abstract":"<p><p>Cannabidiol (CBD), a non-psychoactive compound from Cannabis sativa, shows promise as a therapeutic agent for conditions associated with inflammation and oxidative stress, often involving nitric oxide (NO) signaling dysregulation. This review summarizes preclinical and clinical data on CBD's impact on nitric oxide synthase (NOS) isoforms and NO levels in cardiovascular, neurological, metabolic, and immune systems. Studies suggest that CBD can reduce inflammation-induced inducible NOS (iNOS) expression while maintaining or enhancing endothelial NOS (eNOS)-mediated NO production, leading to decreased oxidative stress, improved endothelial function, and reduced neuroinflammation. The effects of CBD vary based on dose, formulation, timing, and disease state, with potential interactions with metabolites and other drugs affecting safety. Further research is needed to determine optimal dosing, formulation, pharmacokinetics, metabolite profiles, and long-term safety for specific conditions.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"71"},"PeriodicalIF":4.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Methods for Research on Cannabis: A Workshop Report.","authors":"Jonathan M Samet, Jessica Barrington-Trimis, Lisa Bero, Ashley Brooks-Russell, Meghan Buran, Julia Dilley, Darin Erickson, Marilyn Huestis, Kent Hutchison, Thomas L Jeanne, Michael Kosnett, David J Kroll, Stephen Lankenau, Richard Miech, Rosalie Liccardo Pacula, Paula Riggs, Neeloofar Soleimanpour, Steven Teutsch, Gregory Tung, George Sam Wang","doi":"10.1186/s42238-025-00314-7","DOIUrl":"10.1186/s42238-025-00314-7","url":null,"abstract":"<p><strong>Aims: </strong>Progressive legalization of medical and recreational cannabis markets at the state-level has led to rapid growth of medical and recreational cannabis markets and to product diversification with emerging products having high concentrations of delta-9-tetrahydrocannabinol. Research on these products is still limited and the evidence available for policy formulation is diminished by methodological limitations.</p><p><strong>Methods: </strong>As a step towards addressing these limitations, the Colorado School of Public Health convened a multidisciplinary workshop that addressed four areas of cannabis research: epidemiological, clinical, surveillance, and policy. Workshop participants provided recommendations in each area to advance research on cannabis to make it more informative for decision-making on key policy topics. Emphasis was placed on assessment of use of cannabis products by study participants.</p><p><strong>Results: </strong>Recommendations for research methods and their implementation were made in the four areas. Those for epidemiology include using a core set of exposure assessment measures across three domains; developing this core set through a national and/or international scientific consensus process; ensuring the core set of measures are validated and readily available; and updating the core set periodically to account for ongoing changes in the cannabis landscape. Recommendations in the clinical research area include standard dosing and dosing terminology; standardized data collection instruments; identifying biomarkers for detecting cannabis exposure; and biological matrices. Policy research recommendations were offered for state regulators, evaluators/researchers, and policy makers. Surveillance recommendations include developing and implementing a novel and nimble surveillance system to monitor use of high-concentration forms of cannabis; adding questions to existing surveillance systems with the objective of monitoring high-concentration cannabis and adverse outcomes; and elevating the coordination, synthesis, and dissemination of findings in existing data sources that could signal adverse outcomes from high-concentration cannabis.</p><p><strong>Conclusions: </strong>Given the changing marketplace, it is urgent to improve the informativeness of cannabis research through enhanced research methods.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"69"},"PeriodicalIF":4.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ABCB1 polymorphisms are associated with clinical response to nabiximols in patients with multiple sclerosis-related spasticity.","authors":"Alessandra Gemma, Marco Mauri, Paola Banfi, Maurizio Versino, Alen Zollo, Filippo Martinelli Boneschi, Franca Marino, Marco Cosentino, Marco Ferrari","doi":"10.1186/s42238-025-00333-4","DOIUrl":"10.1186/s42238-025-00333-4","url":null,"abstract":"","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"72"},"PeriodicalIF":4.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The influence of religion on physicans` and nurses` attitudes toward medical cannabis in Northern Israel.","authors":"Loay Zaknoun, Salman Zarka, Ygal Plakht, Orli Grinstein-Cohen","doi":"10.1186/s42238-025-00331-6","DOIUrl":"10.1186/s42238-025-00331-6","url":null,"abstract":"<p><strong>Background: </strong>The use of medical cannabis has been increasing significantly worldwide, including in Israel, a country characterized by substantial religious diversity. This study examines the influence of religion on physicians' and nurses' attitudes toward medical cannabis use, focusing on four primary religions in Northern Israel: Judaism, Islam, Christianity, and the Druze faith.</p><p><strong>Methods: </strong>A descriptive cross-sectional study was conducted at the Ziv Medical Center in Northern Israel, involving 395 physicians and nurses. Participants completed a structured questionnaire based on a modified version of the Medical Marijuana Questionnaire (MMQ), assessing their attitudes toward the medical benefits and risks of cannabis. Data were analyzed using ANCOVA and mixed-design ANCOVA models, controlling for covariates including age, gender, religiosity, profession, educational level, and exposure to cannabis use among acquaintances.</p><p><strong>Results: </strong>Statistical analyses revealed significant differences in attitudes toward medical cannabis across religious groups. After adjusting for demographic and background variables, Jewish and Christian participants reported significantly more favorable attitudes regarding the medical benefits of cannabis, while Muslim and Druze participants emphasized its associated risks. A significant interaction was also found between religious affiliation and attitude type (benefits vs. risks), indicating that religious affiliation moderated the relative evaluation of cannabis's therapeutic potential versus its harms. These findings suggest that each religion's unique cultural and ethical frameworks shaped participants' attitudes. The more permissive attitudes observed among Jewish and Christian participants reflect religious principles that emphasize alleviating suffering, while the cautious attitudes of Muslim and Druze participants align with stricter interpretations of religious guidelines.</p><p><strong>Conclusions: </strong>This study identified significant differences in attitudes toward medical cannabis among physicians and nurses from different religious backgrounds in Northern Israel. Jewish and Christian participants expressed more favorable views regarding its medical use, while Muslim and Druze participants exhibited more cautious attitudes. These findings underscore the need for culturally and religiously tailored education and policies to facilitate the integration of medical cannabis into clinical practice.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"70"},"PeriodicalIF":4.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"It's legal, now what?\" development, implementation, and evaluation of interdisciplinary cannabis education for healthcare trainees.","authors":"Sean P Cronin, Josue Cruz, Elena Cameron, Sabrina Azemar, Steven Dudley, Tally M Largent-Milnes, Benjamin R Brady, Jessica S Wallace, Margie R Arnett, Stephen M Dahmer, Mohab M Ibrahim, Alyssa R Padilla, Todd W Vanderah, Jennifer S De La Rosa","doi":"10.1186/s42238-025-00321-8","DOIUrl":"10.1186/s42238-025-00321-8","url":null,"abstract":"<p><strong>Background: </strong>Healthcare professionals are motivated to improve their cannabis knowledge-yet few training opportunities exist. The unique legal status of cannabis, lack of rigorous research, and rapid expansion of consumer demand present challenges to the development and implementation of cannabis education for healthcare professionals and trainees. As a result, an alarming gap in quality of care is developing: health care professionals across disciplines lack the knowledge needed to counsel their patients, even as cannabis use rapidly accelerates.</p><p><strong>Methods: </strong>We aimed to address the gap by developing and implementing an interprofessional cannabis training for healthcare trainees. Considering the challenges to development and implementation of cannabis training, we identified 4 implementation strategies to maximize training quality, uptake, and utility: 1) incorporating a diverse array of scientific expertise and perspectives in curriculum development; 2) offering a comprehensive, evidence-based treatment of potential risks and potential benefits; 3) using an interprofessional training format; 4) adopting a person-centered lens with special emphasis on patient-provider communication. A post-survey evaluated implementation success and intermediate outcomes in trainee attitudes and behavioral intentions that would suggest high potential to deliver healthcare improvements at scale.</p><p><strong>Results: </strong>The virtual training \"It's Legal, Now What? Cannabis Epidemiology, Treatment, and Safety Recommendations\" was successfully implemented; since 2023 a total of 345 trainees in Pharmacy, Nursing, Public Health, and Medicine have earned certificates. Evaluation results are encouraging: 90% agree the training addressed a training need in their current role, 83% agree it should be required for trainees in their profession, 98% and 96% agree it comprehensively addressed potential risks and benefits, respectively, 94% agree it was inclusive of diverse perspectives, 94% agree it improved their knowledge of community resources, 96% report improved ability to respond to patients interested in cannabis, 96% report greater likelihood of providing information on cannabis to others, and 97% of trainees agree they learned information that would help them in their work or community.  CONCLUSIONS: We present our training development process, implementation strategy, and evaluation as an adaptable model for contexts where both recreational and medical use of cannabis are legal.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"68"},"PeriodicalIF":4.3,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socioeconomic status and adolescent cannabis use: a Swedish cohort study.","authors":"Patrik Karlsson, Mats Ekendahl, Isabella Gripe, Jonas Raninen","doi":"10.1186/s42238-025-00334-3","DOIUrl":"10.1186/s42238-025-00334-3","url":null,"abstract":"<p><strong>Background: </strong>The evidence is mixed regarding how socioeconomic status (SES) it is related to cannabis use among adolescents. This study assessed the association between parental SES, measured as the highest level of completed education, and past 12 month cannabis use in older adolescents.</p><p><strong>Method: </strong>Self-reported survey data from the first and second wave of a nationwide cohort study (Futura01) were used (n = 3328). Register information on parental education was linked to the survey data. Two measures of cannabis use were considered: any use during the past 12 months, and use 10 + times during the past 12 months. Control variables included demographics, family and school variables, conduct and emotional problems, and cannabis use at baseline. Multilevel Poisson regression was used to assess the associations.</p><p><strong>Results: </strong>Adolescents having parents with low SES had a lower risk for any cannabis use during the past 12 months, ranging from RR = 0.71 (95% CI = 0.49-1.01) in the unadjusted model to RR = 0.61 (95% CI = 0.42-0.87) in the most adjusted model compared to adolescents with parents having high SES. Compared to those with parents with high SES, those with parents with intermediate SES had lower risk for any cannabis use past 12 months, with RRs ranging from 0.79 (95% CI = 0.59-1.07) in the unadjusted model to RR = 0.71 (95% CI = 0.53-0.95) in the fully adjusted model. For use 10 + times, non-significant associations were observed.</p><p><strong>Conclusion: </strong>Adolescents with parents with lower SES had a lower risk of any past 12 months cannabis use. For more frequent use, no statistically significant associations were observed.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"67"},"PeriodicalIF":4.3,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12455840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145133177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}